(c) 2024 PillSync.com

trizivir abacavir sulfate lamivudine and zidovudine tablet film coated

1 INDICATIONS AND USAGE TRIZIVIR is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. Limitations of Use: • Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (greater than 100,000 copies per mL) [see Clinical Studies ( 14 )] . TRIZIVIR, a combination of abacavir, lamivudine, and zidovudine, each nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. ( 1 )

viiv healthcare company


11 minutes ago OVAL BLUE GX LLI trizivir abacavir sulfate lamivudine and zidovudine tablet film coated

OVAL BLUE GX LLI

16 HOW SUPPLIED/STORAGE AND HANDLING TRIZIVIR is available as tablets. Each tablet contains 300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine. The tablets are bluegreen capsule-shaped, film‑coated, and imprinted with GX LL1 on one side with no markings on the reverse side. They are packaged as follows: Bottles of 60 tablets (NDC 49702-217-18). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature).


More pills like OVAL GX LLI












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site